We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.30 | 0.68% | 44.24 | 44.47 | 43.728 | 43.87 | 13,246,791 | 23:44:52 |
From May 2021 to May 2024
By Colin Kellaher
Bristol Myers Squibb Co. on Tuesday said the European Commission approved the expanded use of its multiple-sclerosis drug Zeposia for the treatment of adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease.
The New York biopharmaceutical company said the approval covers patients who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Bristol Myers last year received U.S. and European approval for Zeposia in adults with relapsing forms of multiple sclerosis and earlier this year received U.S. Food and Drug Administration approval for the drug ulcerative colitis. The company is also evaluating the drug as a treatment for Crohn's disease.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 23, 2021 07:29 ET (12:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
